A new treatment to help clear bacterial infections from the lungs
Official title: ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung
Funded at Eldec Pharmaceuticals, INC. · NIH-10453601 · Data updated 2026-11-12
This study is testing a new treatment called ELD607 to help people with hospital-acquired pneumonia clear bacteria from their lungs more effectively, especially those caused by tough-to-treat germs, and it might be given through inhalation to boost your body's ability to fight off these infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eldec Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Durham, UNITED STATES) |
| Project start | June 22, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2022 |
| Award (this year) | $988,238 |
| NIH project number | 5R42AI155107-03 |
| Project ID | NIH-10453601 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be patients diagnosed with hospital-acquired pneumonia caused by antibiotic-resistant bacteria.
✕Less likely to help
Patients with pneumonia caused by non-resistant bacteria or those who do not have hospital-acquired pneumonia may not benefit from this research.
What this research studies
This research investigates a novel treatment called ELD607, which aims to improve the clearance of bacteria from the lungs in patients with hospital-acquired pneumonia (HAP). The approach focuses on inhibiting a specific ion channel, Orai1, which is involved in inflammation and bacterial infection. By using a peptidomimetic that is more resistant to degradation, the treatment seeks to enhance the body's immune response against antibiotic-resistant bacteria like Pseudomonas aeruginosa and Staphylococcus aureus. Patients may receive this treatment through inhalation, potentially leading to better outcomes in managing severe lung infections.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from severe bacterial lung infections, particularly those resistant to traditional antibiotics.
How similar studies have gone: While the approach of targeting ion channels for bacterial clearance is innovative, similar strategies have shown promise in other contexts, indicating potential for success.
Where this research is happening
-
Eldec Pharmaceuticals, INC.
Durham, United States Active
Researchers
- Principal investigator: Tarran, Robert — Eldec Pharmaceuticals, INC.
- Study coordinator: Tarran, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.